de Wit, Jaron G.
Vonk, Jasper
Voskuil, Floris J. http://orcid.org/0000-0003-3740-4554
de Visscher, Sebastiaan A. H. J. http://orcid.org/0000-0001-8964-5427
Schepman, Kees-Pieter
Hooghiemstra, Wouter T. R.
Linssen, Matthijs D.
Elias, Sjoerd G.
Halmos, Gyorgy B.
Plaat, Boudewijn E. C. http://orcid.org/0000-0001-8631-7727
Doff, Jan J. http://orcid.org/0000-0002-1618-2588
Rosenthal, Eben L.
Robinson, Dominic
van der Vegt, Bert http://orcid.org/0000-0002-2613-1506
Nagengast, Wouter B.
van Dam, Gooitzen M.
Witjes, Max J. H. http://orcid.org/0000-0002-4135-3246
Funding for this research was provided by:
KWF Kankerbestrijding (RUG 2015-8084)
Article History
Received: 31 December 2022
Accepted: 21 July 2023
First Online: 16 August 2023
Competing interests
: G.M.v.D. is CEO of Tracer Europe B.V./AxelaRx. B.v.d.V. is a member of the Scientific Advisory Board of Visiopharm, for which compensation is received by the University Medical Centre Groningen. The remaining authors declare no competing interests.